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Emerging Justi"cations for Placebic Treatment
Tejas Pulisetty
I spent the summer of 2011 collecting data for my glob-
al health research in the urban and rural locales of eastern 
Ghana. Besides learning how to say “Do you have any organic 
chicken le%?” in the native Twi dialects, and how not to dance 
to the music of the pop star Amako, I learned of the depth of 
an inveterate ethical dilemma.
During the daily eye health outreaches in the rural villages 
where I volunteered, one of the Ghanaian ophthalmologists 
would routinely prescribe tetracycline ointments for patients, 
despite believing that the patients were perfectly healthy. 
When we asked why, he responded, “!ey come here because 
they feel that they need a checkup. When they go home with 
something in their hands, they feel satis#ed and happy that 
they received a tangible treatment from the clinic.”
!e reader may sense something amiss here, but at the mo-
ment, I didn’t think much of it. Perhaps it was merely a cul-
tural di&erence that I was unaware of—or perhaps the doctor 
was on to something.
It turns out that clinicians routinely prescribe unnecessary 
medications much more frequently than was previously 
known—and this occurs not only in Ghana, but also in devel-
oped countries.
For instance, in the United States, it is not entirely impossible 
to imagine a scenario in which a patient walks into a clinic 
and the doctor has a diagnosis that is so di"cult to make that 
the doctor ends up giving the patient a medication that they 
know will not biochemically or physically address the patient’s 
condition. !is is con#rmed statistically—an investigation of 
3,848 patient visits over a one year period to an established 
general practice revealed that in roughly half of all initial gen-
eral practice patient-doctor consultations, a #rm diagnosis 
could not be made as a result of the patient presenting with 
vague symptoms instead of a speci#c chief complaint.1 Why, 
then, would the doctor choose to provide the patient with a 
medication that is not biochemically or physically proven to 
address the symptoms? Because such treatments have been 
shown to work for many decades in a variety of scenarios.
A 1987 British study divided a collection of 200 patients, for 
whom no clinical diagnoses could be made, into separate 
groups. One group received honest feedback and was told 
that the clinician did not know what caused their problems. A 
second group received false feedback and was not only given a 
speci#c diagnosis, but was also told that they would de#nitely 
get better in the next several days. Interestingly, this second 
group was more than 64% more likely to experience an im-
provement in symptoms than the other group.2 If this is the 
case, why doesn’t every caregiver do this?
In real clinical scenarios, placebic treatment is a controver-
sial grappling between the bioethical principles of autonomy 
and bene#cence. Placebos are inert substances or treatments 
that are prescribed for psychological rather than physiological 
bene#t. In order for placebos to work, the personal interac-
tions between a caregiver and a patient must somehow convey 
to the patient a suggestion of a positive outcome. If the sug-
gestion is unintentional on the part of the caregiver, it is not 
considered a form of deception.3 !e suggestion may also be 
honest and intentional yet incomplete. For instance, the phy-
sician may say to the patient, “I am prescribing a pill which 
research suggests can be of bene#t to you. In your circum-
stances, I have reason to believe that it will work with minimal 
side e&ects.”4 !is can be considered a mild form of deception 
because the patient is intentionally led to believe that he or she 
is getting a real physiological treatment instead of a placebo. 
In this situation, the deception clearly prioritizes bene#cence 
and violates patient autonomy. Or does it?
It can be argued that the decision to give the patient an honest 
and informed de#nition of the placebic treatment could po-
tentially dissuade the patient from receiving the placebo, thus 
leading the patient to choose to go untreated and e&ectively 
eliminating the option to be treated. Ultimately, this would re-
sult in a paradoxical loss of autonomy from the patient’s per-
spective.4 Bennet Foddy, a senior research fellow at the Ox-
ford Institute for Science and Ethics, notes that “whether the 
patient takes the placebo or refuses it, the pharmacological 
outcome is the same,” considering that a placebo is inert. Fur-
thermore, Foddy states that “the only di&erence is that in one 
case, the patient forms a self-bene#ting false belief.”4 By this 
logic, it would seem that prescribing a placebo results in a net 
gain for the patient. Indeed, the theme here is that the patient’s 
right to refuse a thoroughly-explained and unveiled placebic 
treatment is overridden by the potential bene#ts a patient can 
receive from a placebo and the drug’s inert nature.4 
In further support of placebo use, Professor Foddy provoca-
tively adds:
Doctors have a duty to do the best they can to relieve a 
patient’s symptoms. If that means they prescribe a placebo, 
or even conduct a séance…then there is a duty to do these 
things. If a doctor can really suggest to a patient that a 
chant will cure his headache, then it very likely will, and 
she should ululate it at the top of her lungs…It is a type of 
deception that patients ought to be thankful for, just as we 
are thankful when we receive a mendacious compliment 
from a friend.4
Overall the support for placebic treatments is argumenta-
tively diverse, and the umbrella argument of proponents for 
placebos is that physicians are obligated to do the best they 
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can to relieve a patient’s symptoms.5 An interesting observa-
tion is that placebic treatments may, in certain cases, be one 
of the best possible treatments. For example, placebos have 
been shown to be unusually e&ective in psychiatric depres-
sion as well as irritable bowel syndrome (which may involve 
a substantial psychiatric component).5 Proponents also point 
out that placebic treatments are o%en signi#cantly less costly 
than treatments such as antibiotics or diagnostic tools such as 
MRI, both of which are not always deemed necessary in initial 
patient-physician encounters.
However, the opposition is just as robust on the other side. 
Even though placebic treatments are currently less costly than 
true pharmacological treatments or diagnostic tools, pre-
scription drugs in general add to a national burden of drug 
costs, and placebic drugs may further contribute to this bur-
den in the future. In fact, it was recently shown that the more 
expensive a placebo is, the stronger its therapeutic e&ect may 
become.6 Furthermore, prescription drugs, via incorrect dos-
age or unintended use, have been shown statistically to kill 
106,000 Americans per year, and prescribing excessive, cost-
ly, and physically unnecessary medications is an obviously 
condemnable habit.7,8 Additionally, while emphasizing the 
violation of basic principles of the doctor-patient relation-
ship, those who oppose and question placebic treatments also 
contend that such treatments indirectly lead to hazardous 
results. !ese opponents further believe that placebic treat-
ment should not be used in a real clinical setting but should be 
strictly limited to laboratory clinical trials. A%er all, resorting 
to clinically unsubstantiated treatments may delay a proper 
diagnosis of a serious illness.7 !us, there exists a solid body of 
opposition to such behavior by doctors. In fact, the American 
Medical Association delineated an ethical policy that prohib-
its the deceptive use of placebos in clinical practice, in which 
physicians are barred from giving patients “a substance…that 
the physician believes has no speci#c pharmacological e&ect 
upon the condition being treated.”9 Additional data is needed 
to better describe the relative amount of opposition and sup-
port of placebos by professionals.
One survey revealed that approximately “half of [all] internists 
and rheumatologists” in the U.S. routinely prescribe placebic 
treatments for patients with debilitating chronic conditions.10 
In an Israeli hospital, a retrospective questionnaire revealed 
that 37% of physicians prescribed placebos at least once per 
month, and 94% of all placebo-prescribers believed they were 
e&ective.11 A Danish survey estimated that 48% of Danish cli-
nicians prescribed placebos more than ten times in a given 
year, and that 46% believed that placebic treatments are ethi-
cally acceptable.12 A Canadian survey found that 80% of clini-
cians in one hospital admitted to using placebos at least once 
in a given year.13 Finally, a New Zealand survey “indicated that 
almost all [general practitioners] surveyed would deliberately 
use a [placebic] treatment under some circumstances.”14
Regardless of the interpretations of modern data, the strength 
of the support, or the force of the opposition, placebic treat-
ment will remain an option that is very useful for some pa-
tients and less useful to others. Although this debate has 
historically been level, the modern ethical ar-
guments presented here, in combination with 
the evidence of positive support by health pro-
fessionals and students, seems to show substan-
tial ethical rationale and professional support for the use of 
placebos in clinical practice. Placebos are “the most common-
ly prescribed drug across cultures and throughout history,” 
and as aforementioned, there is violation of neither patient 
autonomy nor bene#cence in the use of placebos.2 Although 
one cannot assert with certainty that the Ghanaian ophthal-
mologist who prescribed tetracycline that summer should be 
commended for his behavior, it is apparent that he has done 
no harm and has not strayed from the societal nor profession-
al guidelines of modern medicine.
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